Renewed US pressure on pharmaceutical pricing, including the emergence of Most Favored Nation concepts under the Donald Trump administration, should not be dismissed as irrelevant to Australian policy debates or characterised as an illegitimate intrusion into domestic decision-making. …
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News -
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL presses ahead with transformation as earnings slip and leadership changes
February 11, 2026 - - Latest News -
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 - - Latest News -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News